A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs) Meeting Abstract

  

Authors:	Johnson, M. L.; Hart, E. M.; Rademaker, A.; Weitner, B. B.; Urman, A.; Simm, H. D.; Fountas, L. M.; Worden, R.; Patel, J. D.; Miller, V. A.; Riely, G. J.
Abstract Title:	A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)
Meeting Title:	49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	15 Suppl.
Meeting Dates:	2013 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-05-20
Language:	English
ACCESSION:	WOS:000335419602517
PROVIDER:	wos
DOI:	10.1200/jco.2013.31.15_suppl.8036
Notes:	Meeting Abstract: 8036 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/128706